Kirin-Amgen Inc v Hoechst Marion Roussel Ltd

Suffolk Los Angeles Adds Experienced Leader Abel Gonzalez as Executive Vice President, Operations, to Drive Strategic Growth and Operational Excellence

Retrieved on: 
Thursday, October 12, 2023
Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Building Systems, California State University, Construction, Kaiser Permanente, Pharmaceutical engineering, Construction management, DPR, LEED AP, International Society, Engineering, Society, University, Biotechnology, University of Southern California, AC, Lean Construction Institute, Health, Education, Green, California Institute for Telecommunications and Information Technology, California Institute of Technology, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Los Angeles Convention Center, Healthcare engineering, Takeda Pharmaceutical Company, Housing, Management, Nursing, Operation

Suffolk , one of the largest and most innovative real estate and construction enterprises in the country, has announced the strategic addition of industry veteran Abel Gonzalez, LEED AP, to its Los Angeles leadership team as Executive Vice President of Operations.

Key Points: 
  • Suffolk , one of the largest and most innovative real estate and construction enterprises in the country, has announced the strategic addition of industry veteran Abel Gonzalez, LEED AP, to its Los Angeles leadership team as Executive Vice President of Operations.
  • View the full release here: https://www.businesswire.com/news/home/20231012590670/en/
    Industry veteran Abel Gonzalez joins Suffolk Los Angeles as Executive Vice President, Operations.
  • “I’m grateful for the opportunity to join the Suffolk team and play an important role in its strategic growth in the West Coast region,” said Mr. Gonzalez.
  • “Suffolk is a leader in leveraging innovative technologies and proven systems to streamline the construction process and deliver exceptional results for clients.

Global Musculoskeletal Disorders Drugs Market to Surge, Projected to Reach $109.4 Billion by 2029 with 4.2% CAGR - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 13, 2023
Health, Pharmaceutical, Online, Osteoarthritis, Prevalence, Route of administration, Arena Pharmaceuticals, Arthritis, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Analgesic, COVID-19, Distribution (marketing), Ageing, Microsoft, Bone, DSM-IV codes, MicroRNA, Life expectancy, Musculoskeletal disorder, Hospital, Arthropathy, Market, Administration, Back pain, Disease-modifying antirheumatic drug, Compound annual growth rate, UCB, Acquisition, AbbVie, Eli Lilly and Company, Pharmacy, Human musculoskeletal system, Growth, Johnson & Johnson, Immunology, Merck & Co., Novartis, Pharmaceutical industry, Agriculture, Pfizer

The global Musculoskeletal Disorders Drugs Market is set to witness significant expansion, projected to reach a substantial value of $109.4 billion by 2029, with a steady Compound Annual Growth Rate (CAGR) of 4.2% during the forecast period.

Key Points: 
  • The global Musculoskeletal Disorders Drugs Market is set to witness significant expansion, projected to reach a substantial value of $109.4 billion by 2029, with a steady Compound Annual Growth Rate (CAGR) of 4.2% during the forecast period.
  • The rise in life expectancy and aging population leads to a surge in musculoskeletal diseases, boosting the demand for treatments and subsequently propelling market expansion.
  • High Prevalence of Musculoskeletal Diseases: Over 150 diseases and conditions fall under the category of musculoskeletal disorders, affecting individuals globally.
  • The prevalence of these disorders, such as arthritis, osteoarthritis, and back pain, drives the demand for drugs and treatment options.

Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Retrieved on: 
Tuesday, September 5, 2023
Treasury, Amgen, Common stock, Employment, University, Eteplirsen, Therapy, General counsel, International, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, IBD, Sarepta, Cornell Law School, Arthur Andersen, Record, Corporate law, MBA, Dartmouth College, Inflammatory bowel disease, Sarepta Therapeutics, Rope, Comparative law, Acquisition, Doctor of Philosophy, Patient, Corporation, CPA, Sanofi, Security (finance), TL1A, BA, Pharmaceutical industry, Management

WALTHAM, Mass., Sept. 5, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Scott Burrows, as Chief Financial Officer and Heidy Abreu King-Jones as Chief Legal Officer and Corporate Secretary. Both will report to Cameron Turtle, Chief Operating Officer of Aeglea, and join the Company's leadership team. Aeglea also announced that Jonathan Alspaugh, Aeglea's current President and Chief Financial Officer, is expected to transition into a strategic advisory consulting role through December 31, 2023.

Key Points: 
  • Both will report to Cameron Turtle, Chief Operating Officer of Aeglea, and join the Company's leadership team.
  • "Scott and Heidy both bring extraordinary expertise and leadership skills through their proven track records at public biopharma companies with both investigational and commercialized products," said Cameron Turtle, DPhil.
  • On behalf of the management team and Board of Directors, I would also like to thank Jonathan for his steadfast commitment to the company."
  • Mr. Burrows is a veteran of the biopharma industry with more than two decades of diverse experience and a proven track-record in biopharmaceutical finance leadership roles spanning multiple public companies.

Blanchard® and Amgen Win Bronze Brandon Hall Group Excellence Award for Best Unique or Innovative Learning and Development Program

Retrieved on: 
Thursday, August 24, 2023
Learning, Senior, Partnership, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Biotechnology, Core, Blanchard, Innovation leadership, SAN, Authority, Tutoring, Amgen

SAN DIEGO, Aug. 24, 2023 /PRNewswire/ -- Blanchard ®, a global pioneer in leadership development, consulting, and coaching for more than 40 years, won a coveted Brandon Hall Group Bronze award for excellence in the Best Unique or Innovative Leadership Program category.

Key Points: 
  • SAN DIEGO, Aug. 24, 2023 /PRNewswire/ -- Blanchard ®, a global pioneer in leadership development, consulting, and coaching for more than 40 years, won a coveted Brandon Hall Group Bronze award for excellence in the Best Unique or Innovative Leadership Program category.
  • The award was announced on August 17, during a live webinar hosted by Brandon Hall Group.
  • The Leading without Authority Learning Journey that won the Bronze award for Best Unique or Innovative Leadership Program was created in partnership with Amgen, Inc., one of the world's leading independent biotechnology companies.
  • The program is an innovative multimodality learning approach that includes eight digital self-paced learning sprints, multiple learning modalities that present Blanchard content, virtual application sessions, and cohort collaboration groups.

Spectral Medical Appoints Former FDA Director, Dr. David W. Feigal, Jr., to Its Board of Directors

Retrieved on: 
Tuesday, June 27, 2023
CDER, University of California, San Diego, Drug, Medicine, CDRH, University, Senior, Office of Inspector General, U.S. Department of Health and Human Services, Berkeley, Stanford University, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Biotechnology, Public, FDA Center for Devices and Radiological Health, Septic shock, CDO, Bangladesh Technical Education Board, Sepsis, Food and Drug Administration, Public health, Partner, MD, Division, PMX, Center for Drug Evaluation and Research, TSX, Knowledge, FDA, Device, Biostatistics, Food, World Health Organization, European Medicines Agency, Pharmaceutical industry, Research

Dr. Feigal brings over four decades of experience in regulatory affairs and clinical research of medical devices, biologics, and products in multiple therapeutic areas.

Key Points: 
  • Dr. Feigal brings over four decades of experience in regulatory affairs and clinical research of medical devices, biologics, and products in multiple therapeutic areas.
  • He has an extensive track record of international regulatory success with the approval/clearance of medical products in numerous therapeutic areas.
  • “We are extremely proud to have Dr. Feigal join our Board of Directors,” commented, Anthony Bihl, Chairman of the Board at Spectral Medical.
  • We look forward to his contributions to Spectral and aiding in the advancement of PMX to market.”

Jacmel Growth Partners Appoints Mark Hardaway as Chief Financial Officer

Retrieved on: 
Wednesday, May 10, 2023
Butler University, Amgen, Partnership, University, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Risk management, Partner (business rank), MBA, Eli Lilly, Treasury, University of North Carolina at Charlotte, Growth, MHA, Commerce, Management

NEW YORK, May 10, 2023 /PRNewswire/ -- Jacmel Growth Partners ("Jacmel"), a minority-owned, private investment firm focused on working with midsize companies, announced today the appointment of Mark Hardaway as Chief Financial Officer.

Key Points: 
  • NEW YORK, May 10, 2023 /PRNewswire/ -- Jacmel Growth Partners ("Jacmel"), a minority-owned, private investment firm focused on working with midsize companies, announced today the appointment of Mark Hardaway as Chief Financial Officer.
  • In this newly created role, Mr. Hardaway will oversee the financial operations for Jacmel and its holdings, while also working with portfolio company leadership to implement best-in-class financial strategies, risk management and operational practices.
  • Mr. Hardaway has 15 years of experience in senior finance positions across a range of companies and is a successful business owner.
  • I'm thrilled to work so closely with portfolio company finance teams and be part of their next stage of growth," said Mr. Hardaway.

Osteoporosis Awareness and Prevention Month 2023: Healthy Bones Are Always in Style

Retrieved on: 
Monday, May 1, 2023
Exercise, Osteoporosis, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Ageing, Bone density, Bone, UCB, Patient, BHOF, Risk, Bone health, Disease, Dietary supplement

Inspiration for this year's theme, "Healthy Bones Are Always in Style," was drawn from legendary designer and fashion icon, Iris Apfel.

Key Points: 
  • Inspiration for this year's theme, "Healthy Bones Are Always in Style," was drawn from legendary designer and fashion icon, Iris Apfel.
  • BHOF offers a variety of resources to help individuals learn more about osteoporosis and how to maintain strong and healthy bones.
  • Throughout the month of May, BHOF is also hosting and sharing a variety of events to promote bone health awareness.
  • Thank you to Amgen, Inc., UCB, Inc., and BHOF's individual donors for supporting this May's Osteoporosis Awareness and Prevention Month campaign.

Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors

Retrieved on: 
Monday, April 24, 2023
Cocrystal, University, Pharmaceutical Research and Manufacturers of America, BS, Avon Products, Pharmacia, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Schering-Plough, Pharmacia & Upjohn, Bausch, Medication, International Federation of Pharmaceutical Manufacturers & Associations, Coronavirus Scientific Advisory Board, Pharmacy, Novartis, MBA, Doctor of Philosophy, Bausch & Lomb, WarnerMedia, Organization, Warburg Pincus, Chemical engineering, Monsanto, Harvard Business School, Merck, Imperial College London, COCP, Management

BOTHELL, Wash., April 24, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its Board membership to six.

Key Points: 
  • BOTHELL, Wash., April 24, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its Board membership to six.
  • Mr. Hassan’s distinguished 40-year career includes serving in senior executive and director positions at global pharmaceutical companies and leading investment firms.
  • Earlier this month, Cocrystal announced Mr. Hassan’s $2 million investment in the Company through an at-the-market private placement.
  • “It’s an honor to attract such a highly accomplished industry veteran to our Board,” said Roger Kornberg, PhD, Cocrystal Chairman, Chief Scientist and Chairman of the Scientific Advisory Board.

Four Early-Career Cancer Researchers Earn Prestigious Annual Award from NCCN Foundation

Retrieved on: 
Thursday, April 13, 2023
Abstract, Oncology, Pfizer, Senior, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Kidney cancer, FACP, Skin cancer, Cancer, Lung cancer, National Comprehensive Cancer Network, Immunotherapy, YIA, NCCN, ORP, CAR, MD, Palliative care, Conference, Breast cancer, Pharmaceutical industry, Management, AbbVie

PLYMOUTH MEETING, Pa., April 13, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® today announced four winners for the 2023 NCCN Foundation Young Investigator Awards. These annual awards honor up-and-coming leaders in oncology research working to investigate and advance cancer care. The honorees will each receive up to $150,000 in funding for projects that will run over two years. The selection process is overseen by the NCCN Oncology Research Program (ORP) which will also provide oversight.

Key Points: 
  • National Comprehensive Cancer Network's Oncology Research Program to oversee projects focused on kidney cancer, palliative care, detection of early-stage cancer, and racial differences in breast cancer.
  • PLYMOUTH MEETING, Pa., April 13, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® today announced four winners for the 2023 NCCN Foundation Young Investigator Awards .
  • The 2023 NCCN Foundation YIA recipients are:
    Julia Agne, MD, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
    The four researchers, who are all from NCCN Member Institutions, will present their results at a future NCCN Annual Conference.
  • The NCCN Foundation has awarded more than $10.3 million since 2011 through the YIA program, to a total of 70 researchers.

Kidney Month: A Time of Unity and Action on Behalf of 37 Million Living with Kidney Disease

Retrieved on: 
Tuesday, February 28, 2023
Diabetes, Therapy, GSK, Dialysis, Disease, AKF, CSL Vifor, Janssen Pharmaceuticals, Patient, Kidney disease, Kidney, American Kidney Fund, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, AstraZeneca, Hypertension, End Stage Renal Disease Program, Nephrology, Novartis, Caregiver, Stroke, Kidney failure, Pharmaceutical industry

This March, AKF urges those in the kidney community and beyond to come together in support of all those affected by kidney disease.

Key Points: 
  • This March, AKF urges those in the kidney community and beyond to come together in support of all those affected by kidney disease.
  • A highlight of Kidney Month for the kidney community will be AKF’s Kidney Action Week , which will be held March 20-24.
  • Kidney Action Week will include a Congressional Briefing that will highlight the need to address prevention and management of diabetes and hypertension, the two leading causes of kidney failure.
  • In addition to kidney failure, kidney disease can lead to other health problems, including stroke or heart attack.